Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Non-Current Liabilities (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Total Non-Current Liabilities readings, the most recent being $697.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 7.5% year-over-year to $697.2 million, compared with a TTM value of $697.2 million through Dec 2025, up 7.5%, and an annual FY2025 reading of $697.2 million, up 7.5% over the prior year.
  • Total Non-Current Liabilities hit $697.2 million in Q4 2025 for Apellis Pharmaceuticals, up from $654.3 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $697.2 million in Q4 2025, with the low at $302.0 million in Q3 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $591.9 million (2023), compared with a mean of $583.0 million.
  • The largest YoY upside for Total Non-Current Liabilities was 136.93% in 2021 against a maximum downside of 32.73% in 2021.
  • Year by year, Total Non-Current Liabilities stood at $338.0 million in 2021, then skyrocketed by 66.75% to $563.5 million in 2022, then rose by 5.03% to $591.9 million in 2023, then grew by 9.57% to $648.5 million in 2024, then rose by 7.5% to $697.2 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $697.2 million, $654.3 million, and $663.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.